1	Impact of Cushing's syndrome on the hypothalamus-pituitary-gonad axis in
2	women
3	
4	
5	
6	Anting Yu ¹ , Xuan Liu ¹ , Yiyu Chen ¹ , Shuo Li ¹ ,Ming Liu ¹ ,*
7	¹ Department of Endocrinology and Metabolism, Tianjin Medical University General Hospital,
8	Tianjin, China
9	
10	
11	
12	* Correspondence:
13	Ming Liu, mingliu@tmu.edu.cn. 18320017516;
14	Department of Endocrinology and Metabolism, Tianjin Medical University General Hospital,
15	Tianjin, China
16	154 Anshan Road, Heping District, Tianjin 300052, China
17	
18	
19	
20	
21	
22	

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

underlying causes of hypercortisolism.

Abstract Background: The reproductive and sexual disorders commonly occur in patient with Cushing's syndrome (CS), but only few clinical studies focused on the hypothalamus-pituitary-gonad (HPG) axis status in women with CS. A comprehensive spectrum of the impairment on HPG axis in women with CS of different tensity and causes is needed. Method: This retrospective study analyzed the status of HPG axis in 137 women with different CS causes diagnosed between 2007 and May 2024, and the correlation between reproductive hormones and the tensity of hypercortisolism. Receiver operating characteristic (ROC) analysis was performed in 45 women with available data of plasma steroids by tandem mass spectrometry (LC-MS/MS) as well. Results: Women with ectopic adrenocorticotropin (ACTH) secretion (EAS) had significantly higher levels of serum cortisol, 24h urinary-free cortisol (UFC), ACTH, with marked increase in testosterone and decrease in Luteinizing hormone (LH) and Follicle-stimulating hormone (FSH) (P<0.001). The serum cortisol and ACTH were positively associated with testosterone, while negatively associated with LH and FSH, especially in postmenopausal women. Further investigation of steroid profiles found plasma androgen including testosterone, Androstenedione (A2), dehydrospiandrostenedione (DHEA) and dehydrospiandrostenedione sulfate (DHEAS) had high sensitivity and specificity in discriminating CD from adrenal CS. Additional analysis of thyroid axis found hypercortisolism had less influence on TSH compared with LH and FSH. Conclusion: Excessive cortisol caused by CS can impair the HPG axis in women, which were especially intense in EAS. The degrees of impairment were associated with the intensity and the

Keywords: Cushing's syndrome/HPG axis/ectopic ACTH syndrome/serum steroids/mass

spectrometry

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

Introduction Cushing's syndrome (CS), as a chronic and systemic endocrine disease caused by long-term and excessive exposure to glucocorticoids, can leads to a myriad of clinical manifestations and complications. CS traditionally comprises two subgroups: ACTH-dependent CS, which account for 70-80% of CS, and ACTH-independent CS (AI-CS).[1] ACTH-dependent CS is most commonly caused by Cushing's disease (CD) (80-90%), and more rarely ectopic ACTH secretion (EAS) (10-20%), whose discrimination from Cushing's disease is considered challenging[2, 3] .ACTH-independent CS is most frequently caused by unilateral adrenal adenomas (70-80%)[1]. The clinical complications of CS primarily include systematic arterial hypertension, impairment of glucose and lipid metabolism, musculoskeletal disorders, neuropsychiatric disorders, impairment of reproductive and sexual function and dermatological manifestations. Reproductive and sexual disorders commonly occur in patients with CS, and most frequently represented as decreased libido and hypogonadism in men and menstrual irregularity in women[4]. It is widely accepted that the hypothalamus-pituitary-gonad (HPG) axis can be affected by hypercortisolism at different levels, which accounts for the reproductive and sex disorders[5, 6]. Besides, excessive cortisol secretion can also impair the function of hypothalamus-pituitary-thyroid (HPT) axis[7]. Recently, some clinical studies has investigated the impact of CS on HPG axis in men, pointed out that hypercortisolism can lead to reversible hypogonadotropic hypogonadism in men[8, 9]. Though the female predominance exist in CS of different causes[1], only a few studies focused on

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

the HPG status in women with CS in clinic[10-12], and rarely investigated the impairment of different subtypes of CS on HPG axis and its correlation with the tensity of hypercortisolism. Thus the aim of this retrospective study was to investigate the clinical status of HPG axis in women affected by different causes of CS and varying intensity of hypercortisolism. Materials and methods **Setting** This was a retrospective study at the department of Endocrinology and Metabolism at Tianjin Medical University General Hospital. All coded medical records of women patient with CS assessed in routine care between 2007 and May 2024 were analyzed. Clinical evaluation All patient were hospitalized at Tianjin Medical University General Hospital to undergo a full diagnostic work-up. The diagnosis of Cushing syndrome was based on clinical features and at least 2 of the following: (1) 24-h urinary free cortisol excretion (>300 nmol/24 h) in at least 2 samples; (2) 1-mg overnight dexamethasone suppression test (0800 h plasma cortisol>50 nmol/L) [13]; (3) 48 h, 2 mg/d dexamethasone suppression test urinary free cortisol>27 nmol/24 h [14]. Majority of the diagnoses of adrenal Cushing's syndrome was histologically confirmed. The diagnosis of Cushing disease was established if pathological examination of the pituitary surgical specimen confirmed the diagnosis, or if the condition resolved after resection or irradiation of the pituitary gland. The diagnosis of an ectopic cause of ACTH secretion was confirmed by histological examination of surgical or biopsy specimen. Nonetheless, not all sources of ACTH excess were confirmed, in this case, presumed diagnosis was extracted from diagnostic code at

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

discharge. The diagnoses were made at the discretion of the attending physician, based on clinical presentation, results of high-dose dexamethasone test, pituitary MRI, chest and abdominal CT. Hormone assays Preoperative blood samples were obtained in the morning between 06:00 to 08:00 from an 8h fasting blood draw to minimize potential confounding introduced by circadian rhythmicity and food intake. Plasma ACTH, cortisol and 24-h excretion of urinary free cortisol were measured using chemiluminescent enzyme immunoassay (Siemens Healthcare Diagnostics Inc., Erlangen, Germany). The reproductive hormones (FSH, LH, estradiol, testosterone) were measured at the early time of primary diagnosis, and determined by chemiluminescence as well. Only 45 women with CS were available to measure the plasma steroids by MS, and the steroid profile includes the following: progesterone, 17-hydroxyprogesterone, DHEA, DHEAS, androstenedione, testosterone, 11-deoxycorticosterone, 11-deoxycortisol, cortisol, corticosterone and cortisone. After appropriate sample preparation, the blood was centrifuged at 14,000g for 10 minutes. A 100 µL aliquot of the supernatant was then analyzed using a JasperTM high-performance liquid chromatography system coupled with an ABSCIEX Triple QuadTM 4500 MD mass spectrometer, equipped with a heated nebulizer ionization source operating in positive ion mode. Quantification of the data was performed using MultiQuantTM MD 3.0.3 software. Statistic analysis Statistical analysis was performed using GraphPad Prism version 9.0, IBM SPSS Statistics version 25 and R (a language and environment for statistical computing). Standard descriptive analyses were used to summarize the study variables. Shapiro's test was applied to test for normality. For quantitative variables, comparisons between controls and cases at baseline were performed by

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

unpaired Student's t-tests (or Mann-Whitney tests if the distribution of the variable was not log-normal). Comparison between the three subgroups of CS was conducted by ordinary one-way ANOVA in case of homoscedasticity or Kruskal-Wallis instead. The simple linear regression was used to study the association between Cushing's indexes and reproductive outcomes at baseline. The receiver operating characteristic (ROC) curve analysis was performed to test the usefulness of plasma androgens as markers for differentiating between adrenal CS and CD. The optimal cutoff values were determined using the Youden index (sensitivity + specificity -1). A p-value <0.05 was considered statistically significant. Results Demographic and clinicopathological characteristics 287 female patients clinically suspected as Cushing's syndrome were considered for inclusion in this study to begin with. After the exclusion of subclinical CS, iatrogenic CS and patients lacking sexual hormone assays, only 137 women with CS served as study's population, including 63 with adrenal CS, 57 with CD and 17 with EAS. Of note, the source of ectopic ACTH secretion include 5 thymic neuroendocrine tumor, 3 gastrointestinal carcinomas, 2 pheochromocytomas, 1 renal clear cell carcinoma, 1 lung neuroendocrine tumor, 1 small cell lung carcinoma and 1 pancreatic neuroendocrine tumor. Gonadotrope axis in women patient with Cushing's syndrome The basic information and hormonal characteristics of study's cohort are shown in Table 1. No significant difference in body mass index (BMI) were showed. But the mean age of EAS was older than the other two subgroups, comport with previous report [3]. The three subgroups of

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

women with CS have markedly different levels of ACTH (AI-CS<CD<EAS), whereas the intensity of hypercortisolism, represented by serum cortisol and 24h-UFC, only significantly higher in women with EAS (P<0.001). Comparisons of reproductive hormones between women with different CS are detailed in Figure 1. There was no much difference in serum estradiol level between adrenal CS, CD and EAS. Conversely, the testosterone levels significantly increased in women with EAS and CD in comparison with AI-CS (P<0.001), and rather higher in EAS (P<0.001) (Figure 1 A, B). Both circulating LH and FSH levels in women with EAS markedly decreased, showing significant differences with the other two subgroups. But the LH and FSH levels of women with CD did not significantly differ from AI-CS (Figure 1 C, D). Furthermore, the FSH:LH ratios were also calculated and compared, and the EAS showed markedly higher FSH:LH ratio than AI-CS (P<0.001) and CD (P=0.002), while no marked difference existed between AI-CS and CD (supplementary figure S1). Linear regression between hypercortisolism intensity and reproductive hormones in premenopausal and postmenopausal women It is a general consensus that the level of women's reproductive hormones have clear periodicity and regulate the menstruation [15], thus the study's group was further divided into the premenopausal women and the postmenopausal women, detailed in Table 2. As shown, most women with EAS were postmenopausal (premenopause, n=5; psomenopause, n=12), with significantly higher levels of serum cortisol, 24h-UFC, ACTH and testosterone levels, and lower levels of LH and FSH. It is noteworthy that the LH and FSH levels reached a more significant difference in postmenopausal women with EAS in comparison with adrenal CS and CD

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

(Supplementary Figure S2). The serum cortisol and 24h UFC levels did no significantly differ between AI-CS and CD neither in premenopause nor postmenopause women, while the ACTH and testosterone levels were higher in CD than AI-CS in both situations, similar with above (Table 1). The estradiol levels still showed no difference among the three subgroups neither in premenopausal women nor in postmenopausal women. For the sake of investigating the relationship between the tensity of hypercortisolism and the HPG axis impairment, linear regression analyses between serum cortisol and the reproductive hormones were performed, detailed in Figure 2. As shown, in postmenopausal women, serum cortisol was significantly and negatively associated with FSH (P=0.014) and LH (P=0.016), while positively associated with testosterone (P<0.001). Similar analyses were performed in premenopausal women with CS as well, and found that serum cortisol did not significantly associated with LH or FSH. Only testosterone was positively associated with serum cortisol in premenopausal women with CS (P<0.001). Of note, the linear regression curves in postmenopausal women described those relationships better, which are demonstrated by Pearson's correlations[16]. The linear regression between ACTH, 24h-UFC and reproductive hormones are presented in Supplementary Table S1. The results were quiet similar with serum cortisol when studying the relationship between ACTH and reproductive hormones, showing significant correlations with testosterone in both situations, but only in postmenopausal women ACTH did significantly correlate with LH and FSH. Moreover, the 24h-UFC only showed significant correlation with testosterone, and merely did correlate with LH or FSH in neither situations. Still, serum estradiol did not correlate with any parameters of CS in any situations.

The characteristics of steroid profiles in adrenal CS and Cushing's disease

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

The measurement of plasma steroids by MS was only available in 45 women with CS, detailed in Table 3 (AI-CS, n=24; CD, n=21). As shown, plasma androgen including testosterone, A2, DHEA and DHEAS significantly increased in women with CD compared with AI-CD (P<0.001) (Supplementary Figure S3). Additional linear regression analyses between ACTH and DHEA and DHEAS were performed as well, and showed significant and positive association between them (supplementary figure S4), comport with the general acceptance that DHEA and DHEAS are majorly determined by ACTH levels [17]. Except plasma androgen, only 11-Deoxycortisol (P=0.011) and 11-deoxycortisterone (P=0.006) moderately decreased in women with CD. The receiver operating characteristic curve (ROC) analyses were applied to assess the diagnostic power of plasma androgen in differentiating CD from adrenal Cushing's syndrome, and detailed in Table 4 and Figure 3. As shown, the testosterone had a sensitivity of 81.0% and a specificity of 83.3%, with a cutoff value of 172.5 pg/ml and an AUC of 0.816. The androstenedione had a sensitivity of 100.0% and a specificity of 83.3%, with a cutoff value of 917.5 pg/ml and an AUC of 0.829. The DHEA had a sensitivity of 100.0% and a specificity of 87.5%, with a cutoff value of 1170.5 pg/ml and an AUC of 0.972. The DHEA-S had a sensitivity of 100.0% and a specificity of 83.3%, with a cutoff value of 0.27*10^6 pg/ml and an AUC of 0.958. Taken together, all four plasma androgen can effectively discriminate between adrenal CS and CD, with high sensitivity and specificity at the best cutoff, especially DHEA and DHEAS. Thyroid axis in women patient with Cushing's syndrome Due to the Interest in the impact of hypercortisolism on HPT axis, and the high prevalence of thyroid function test, the data of thyroid hormone was also collected, detailed in Table 1 and Figure 4. As shown, only serum FT3 levels in women with EAS markedly decreased compared to adrenal

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

CS and CD (P<0.01), either FT4 nor TSH showed much difference (figure 5A, B). The FT3:FT4 ratios were further calculated and compared, and reflected a more distinguishing difference in EAS compared with AI-CS and CD as well(P<0.001) (Figure 5C), which statistically indicated the prominent effect of cortisol-meditated inhibition on peripheral deiodination [7]. The linear regression analyses between hypercortisolism and thyroid hormones were also performed, detailed in supplementary figure S5. Only the FT3 showed a moderate correlation with serum cortisol, 24h-UFC and ACTH, neither FT4 nor TSH did significantly correlate with any parameters of CS. Discussion This study successfully characterizes the impact of hyercortisolism on gonadotrope axis in women with CS of different causes, and further clarifies its correlation with the intensity of hypercortisolism. The steroids profiles between CD and adrenal CS in a limited group is investigated as well, offering a more profound insight into the changes of sexual hormones. The effects of CS on HPT axis is also mentioned, in comparison with the HPG axis. The primary finding of this study is the distinguishing decrease of LH and FSH, and the marked increase of testosterone levels in women with EAS compared with adrenal CS and CD. It is wildly accepted that EAS is usually associated with more severe hypercortisolism, which was also confirmed in this study, and that glucocorticoids can dose-dependently impair the hypothalamus, pituitary and the reproductive tract in women[1, 5, 6], thus the decrease of LH and FSH is theoretically expected. However, there was no significant difference in estradiol between the three CS subgroups, nor correlation with the tensity of hypercortisolism in neither premenopausal cohort or in the postmenopausal cohort. This may be explained by the dual roles of

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

glucocorticoids in the ovary. The glucocorticoids have been found have both stimulatory and inhibitory effects on ovary, depending on the cortisol dosage, follicular phase or GR isoforms expression, and the function still remains unclear [18]. Moreover, women with EAS had markedly higher FSH:LH ratio, and there has study pointed out that a basal cycle high FSH:LH ratio has a negative impact on follicular development and oocyte quality [19], indicating another possible mechanism by which the gonad was impaired in women with EAS. This study also found significant linear associations between serum cortisol and ACTH versus reproductive hormones, especially in postmenopausal women with CS, which were negative in LH and FSH, while positive in testosterone. Through further dividing the study's group by the menopause, we hope to exclude the influence of menstruation on reproductive hormones. And the result exhibited more fitting models of linear regression for the association between the tensity of hypercortisolism and LH and FSH in postmenopausal cohort, demonstrated by higher Pearson's correlations [16]. Comport with previous studies [5, 6, 18], those results once again confirmed that the function of HPG axis in women can be impaired by hypercortisolism, and is associated with its intensity. Nevertheless, similar with previous study in men, these associations were quite moderate[8], indicating that other influential factors, like personal heterogeneity and underlying cause, also have influence on the degrees of gonadal impairment by hypercortisolism. As mentioned above, the response of testosterone to hypercortisolism was antithetical to LH and FSH, showing that more severe hypercortisolism is associated with higher plasma testosterone in women with CS. Further, the steroids profile by MS showed that testosterone, A2, DHEA and DHEAS were all increased in women with CD compared with AI-CS. Interestingly, this finding is right inverse to the finding in men, which showed that testosterone levels were frequently lower in

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

men with CS and negatively associated with the tensity of hypercortisolism [8, 9, 20]. This phenomenon suggests that the sexual dimorphism exists in testosterone's response to CS. The explanation lies in that the testosterone is mainly secreted by testicle in men, and its secretion can be inhibited by hypercortisolism [20], whereas in women, the testosterone is produced from adrenal (25%), ovary (25%), and circulating A2 (50%), and the A2 is secreted by adrenal (50%) and ovary (50%) as well [21]. As generally accepted, the adrenal androgen production is stimulated by ACTH [22], which is also confirmed by this study's result, presenting significant and positive correlation between ACTH and plasma androgen. Thus in women with CS, the regulation of ACTH on adrenal androgen seemed have a more predominant role than the inhibition of hypercortisolism on gonad. The steroid profiles of CS based on MS is a hot topic recently, many studies have reported that the steroid profiles can help diagnose different subtypes of CS, including clinical and subclinical CS, adrenal CS, CD, EAS and so on [23-26]. The diagnostic power of plasma androgen in discriminating CD and adrenal CS was also analyzed in this study, and found all the four androgen can effectively differentiate CD from adrenal CS. Among them, DHEA and DHEAS can best serve as diagnostic parameters with higher sensitivity and specificity, making them useful supplementary measurement to confirm the causes of CS. This study also investigated the impact of CS on HPT axis, but only found the peripheral inhibitory effect of hypercortisolism, demonstrated by the decreased FT3 and T3:T4 ratio in EAS, and the negative correlation between FT3 and hypercortisolism. The FT4 and TSH showed no significant difference or correlation with hypercortisolism, which seemed contrary to previous study [7, 27]. But this result may imply that the HPG axis was more vulnerable to excessive serum

266

267

268

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

cortisol than the thyroid axis, since the HPG axis seemed more severely impaired than thyroid axis but similar tensity of hypercortisolism. As normal thyroid function is important to maintaining normal reproduction, and thyrotoxicosis and hypothyroidism can cause reproductive and sex disorders in both men and women [28], extra attentions should be paid on HPG axis in those patient with CS and hypothyroidism. The major limitation of this study is its retrospective design, which inevitably leading to selection bias, personal heterogeneity and measurement incompleteness. Besides, the 24h-UFC merely had significant correlations with reproductive hormones in this study, which may attributed to the retrospective design and the high degree of variability in UFC levels [29]. The limited number available to MS is also a limitation, due to the low prevalence of MS, but taken previous studies together [23, 24, 30], the conclusion about the steroid profiles is quiet convincing. The major strength of this study is that it met the need to characterize the clinical spectrum of CS on HPG axis in women with the large population. Though it is wildly received that high dose of glucocorticoid can impair reproductive system [5, 6, 18], only a handful studies reported its clinical status[10-12]. This study further divided the whole cohort by etiology and menopause, and through investigating the differences and associations among different groups, offered more comprehensive insight into the influence of hypercortisolism on HPG axis. The involvement of steroid profile using MS is also the novelty of this study, provided support for plasma androgen in discriminating CD from adrenal CS. Moreover, with the wild use of glucocorticoids, the result of this study highlights the importance to concern the HPG axis status in women with exogenous CS as well, especially in those who seek fertility. In conclusion, the impairment of Cushing's syndrome on hypothalamic-pituitary-gonadal axis in

288

289

290

291

292

293

294

295

296

297

298

299

300

301

302

303

304

305

306

307

308

women is associated with the underlying causes and the intensity of hypercortisolism. Women with ectopic ACTH syndrome incline to show a more severe impairment of HPG axis but higher testosterone levels. Acknowledgments We thank all participants from the Department of Endocrinology and Metabolism at Tianjin Medical University General Hospital. **Funding** This work was supported by the National Key R&D Program of China (grant numbers 2019YFA0802502 and 2022YFE0131400); we acknowledge the support of the National Natural Science Foundation of China (grant numbers 81830025 and 82220108014), Tianjin Key Medical Discipline (Specialty) Construction Project (grant number TJYXZDXK-030A), and Major Project of Tianjin Municipal Science and Technology Bureau (grant number 21ZXJBSY00060). **Ethics approval** The studies involving human participants were reviewed and approved by Institutional Review Board of Tianjin Medical University General Hospital. The ethics committee waived the requirement for written informed consent for participation. **Human participant declaration** Due to the extraction of all patient data from the hospital's electronic medical records and the

310

311

312

313

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

329

330

Int J Mol Sci, 2017. **18**(10).

anonymization of participants' identities, the study waived the requirement for informed consent. statement of authorship Anting Yu participated in data collection and drafting and editing of the paper. Ruixuan Liu, Yiyu Chen and Shuo Li participated in data analysis. Ming Liu participated in revision of the paper. All authors saw and approved the final version and no other person made a substantial contribution to the paper. References 1. Gadelha, M., et al., Cushing's syndrome. Lancet, 2023. 402(10418): p. 2237-2252. 2. Giuffrida, G., et al., Global Cushing's disease epidemiology: a systematic review and meta-analysis of observational studies. J Endocrinol Invest, 2022. 45(6): p. 1235-1246. 3. Hayes, A.R. and A.B. Grossman, Distinguishing Cushing's disease from the ectopic ACTH syndrome: Needles in a haystack or hiding in plain sight? J Neuroendocrinol, 2022. 34(8): p. e13137. Pivonello, R., et al., Complications of Cushing's syndrome: state of the art. Lancet Diabetes 4. Endocrinol, 2016. 4(7): p. 611-29. 5. Whirledge, S. and J.A. Cidlowski, Glucocorticoids and Reproduction: Traffic Control on the Road to Reproduction. Trends Endocrinol Metab, 2017. 28(6): p. 399-415. 6. Joseph, D.N. and S. Whirledge, Stress and the HPA Axis: Balancing Homeostasis and Fertility.

331	7.	Paragliola, R.M., et al., Cushing's Syndrome Effects on the Thyroid. Int J Mol Sci, 2021. 22(6).
332	8.	Papadakis, G.E., et al., Impact of Cushing's syndrome on the gonadotrope axis and testicular
333		functions in men. Hum Reprod, 2023. 38(12): p. 2350-2361.
334	9.	Zheng, H., et al., The hypothalamic-pituitary-gonad axis in male Cushing's disease before and
335		after curative surgery. Endocrine, 2022. 77(2): p. 357-362.
336	10.	Kaltsas, G.A., et al., How common are polycystic ovaries and the polycystic ovarian syndrome
337		in women with Cushing's syndrome? Clin Endocrinol (Oxf), 2000. 53(4): p. 493-500.
338	11.	Akirov, A., et al., Cushing's syndrome in women: age-related differences in etiology and
339		clinical picture. Pituitary, 2023. 26(1): p. 144-151.
340	12.	Keskin, F.E., et al., Sexual function in women with Cushing's Syndrome: A controlled study.
341		Turk J Urol, 2018. 44 (4): p. 287-293.
342	13.	Nieman, L.K., et al., The diagnosis of Cushing's syndrome: an Endocrine Society Clinical
343		Practice Guideline. J Clin Endocrinol Metab, 2008. 93(5): p. 1526-40.
344	14.	Görges, R., et al., Diagnosis of Cushing's syndrome: re-evaluation of midnight plasma cortisol
345		vs urinary free cortisol and low-dose dexamethasone suppression test in a large patient group.
346		J Endocrinol Invest, 1999. 22 (4): p. 241-9.
347	15.	Jabbour, H.N., et al., Endocrine regulation of menstruation. Endocr Rev, 2006. 27(1): p.
348		17-46.

evaluation of scientific publications. Dtsch Arztebl Int, 2010. 107(44): p. 776-82.

Schneider, A., G. Hommel, and M. Blettner, Linear regression analysis: part 14 of a series on

349

350

16.

351	17.	El Asmar, N., et al., The Value of Perioperative Levels of ACTH, DHEA, and DHEA-S and
352		Tumor Size in Predicting Recurrence of Cushing Disease. J Clin Endocrinol Metab, 2018.
353		103 (2): p. 477-485.
354	18.	Bhaumik, S., et al., Glucocorticoids and Their Receptor Isoforms: Roles in Female
355		Reproduction, Pregnancy, and Foetal Development. Biology (Basel), 2023. 12(8).
356	19.	Barroso, G., et al., High FSH:LH ratio and low LH levels in basal cycle day 3: impact on
357		follicular development and IVF outcome. J Assist Reprod Genet, 2001. 18(9): p. 499-505.
358	20.	Ren, L., et al., Dysfunction in Sertoli cells participates in glucocorticoid-induced impairment
359		of spermatogenesis. Mol Reprod Dev, 2021. 88 (6): p. 405-415.
360	21.	Burger, H.G., Androgen production in women. Fertil Steril, 2002. 77 Suppl 4: p. S3-5.
361	22.	Turcu, A., et al., Adrenal androgens and androgen precursors-definition, synthesis, regulation
362		and physiologic actions. Compr Physiol, 2014. 4(4): p. 1369-81.
363	23.	Hines, J.M., et al., High-Resolution, Accurate-Mass (HRAM) Mass Spectrometry Urine
364		Steroid Profiling in the Diagnosis of Adrenal Disorders. Clin Chem, 2017. 63(12): p.
365		1824-1835.
366	24.	Braun, L.T., et al., Delineating endogenous Cushing's syndrome by GC-MS urinary steroid
367		metabotyping. EBioMedicine, 2024. 99 : p. 104907.
368	25.	Masjkur, J., et al., Plasma Steroid Profiles in Subclinical Compared With Overt Adrenal
369		Cushing Syndrome. J Clin Endocrinol Metab, 2019. 104 (10): p. 4331-4340.
370	26.	Eisenhofer, G., et al., Plasma Steroid Metabolome Profiling for Diagnosis and Subtyping
371		Patients with Cushing Syndrome. Clin Chem, 2018. 64(3): p. 586-596.

- 372 27. Shekhar, S., et al., The Hypothalamic-Pituitary-Thyroid Axis in Cushing Syndrome Before and
- 373 After Curative Surgery. J Clin Endocrinol Metab, 2021. 106(3): p. e1316-e1331.
- 374 28. Krassas, G.E., K. Poppe, and D. Glinoer, Thyroid function and human reproductive health.
- 375 Endocr Rev, 2010. **31**(5): p. 702-55.

- 376 29. Petersenn, S., et al., High variability in baseline urinary free cortisol values in patients with
- 377 *Cushing's disease*. Clin Endocrinol (Oxf), 2014. **80**(2): p. 261-9.
- 378 30. Ahn, C.H., et al., Metabolic changes in serum steroids for diagnosing and subtyping Cushing's
- 379 *syndrome*. J Steroid Biochem Mol Biol, 2021. **210**: p. 105856.

Table 1. Characteristics of 137 women with Cushing's syndrome.

	Adrenal Cushing's	Cushing's	ectopic ACTH	P-value
	syndrome	disease	syndrome	
	(n=63)	(n=57)	(n=17)	
Age	40.11±12.60	39.95±11.09	55.65±16.15	< 0.001
(years)				
Body mass index	26.15 ± 4.19	26.92 ± 4.83	27.09±5.31	0.587
(BMI)(kg/m2)				
ACTH	5.00(5.00,6.79)	66.40(46.55,114.00	225.00(123.00,481.	< 0.001
(pg/ml))	00)	
Serum cortisol	30.85 ± 8.75	33.07±11.53	51.04±17.01	< 0.001
(ng/ml)				
Urinary-free cortisol	450.00(193.50,650.	412.20(174.65,592.	1424.50(945.00,208	< 0.001
(mg/24 h)	00)	80)	1.00)	
FSH	4.54(3.00,7.48)	5.18(3.58,8.25)	1.70(0.79,3.32)	< 0.001
(IU/L)				
LH	3.29(1.32,6.21)	2.58(1.06,6.92)	0.16(0.07, 0.39)	< 0.001
(IU/L)				
E2	34.00(15.00,91.00)	32.86(14.71,54.00)	22.80(14.50,31.67)	0.365
(pg/ml)				
T	24.15(17.79,40.23)	52.00(38.77,72.78)	105 50/65 26	< 0.001
(ng/dl)			105.50(65.26,	
			199.80)	
FSH:LH ratio	2.01(1.20,3.87)	2.62(1.64,4.64)	10.83(3.41,20.78)	< 0.001
FT3	3.21 ± 0.66	3.29 ± 0.81	2.64 ± 0.72	0.005
(pmol/L)				

FT4	11.274±1.778	11.556±2.470	11.86±3.54	0.613
(pmol/L)				
TSH	0.69(0.53,1.22)	0.62(0.36,1.14)	0.49(0.23,0.91)	0.097
(uIU/mL)				
FT3:FT4 ratio	0.29(0.25,0.31)	0.28(0.25,0.32)	0.23(0.18,0.27)	< 0.001

Statistically significant results(P<0.05) were highlighted in bold.Comparison between groups was performed using one-way ANOVA or Kruskal-Wallis test if the distribution of the respective variable was not log-normal in any of the groups. ACTH, adrenocorticotrophic hormone; FSH, Follicle-stimulating hormone; LH, Luteinizing hormone; E2, estradiol; T, testosterone; TSH, thyroid-stimulating hormone.

Table2. Characteristics of women with Cushing's syndrome separated by menstruation.

Premenopause	
(n=99)	

	Adrenal Cushing's	Cushing's	ectopic ACTH	P-value
	syndrome	Disease	syndrome	
	(n=50)	(n=44)	(n=5)	
Age (years)	34.98±7.99	35.27±7.53	34.20±9.91	0.953
Body mass index	26.05±4.31	27.88 ± 4.60	30.23 ± 8.59	0.149
(BMI)(kg/m2)				
Serum cortisol	31.22±8.76	32.62±11.46	52.75 ± 3.78	< 0.001
(random)(ng/ml)				
ACTH	5.00(5.00,5.75)	65.55(46.28,108.95)	741.00(123.00,10	< 0.001
(pg/ml)			83.00)	
Urinary-free	490.00(259.75,701.35)	420.70(190.40,584.10	2000.00(1225.00,	0.001
cortisol(mg/24 h))	2306.00)	
FSH(IU/L)	4.08(3.07,6.43)	4.84(3.90,6.14)	2.300(1.10,10.37)	0.392
LH(IU/L)	2.59(1.29,5.04)	2.57(1.13,5.51)	0.40(0.35,1.00)	0.009
E2(pg/ml)	47.00(21.54,97.65)	36.00(22.50,62.06)	28.72(26.29,135.5	0.620
			0)	
T(ng/dl)	24.42(16.71,41.21)	52.48(41.48,71.40)	244.20(139.95,	<0.001
			457.46)	

Postmenopause (n=38)

		(/		
	Adrenal Cushing's	Cushing's	ectopic ACTH	P-value
	syndrome	Disease	syndrome	
	(n=13)	(n=13)	(n=12)	
Age (years)	59.85±5.24	55.77±4.34	64.58±6.88	0.001
Body mass index	26.55 ± 3.85	23.67±4.24	26.79 ± 4.51	0.127
(kg/m2)				
Serum cortisol	29.41 ± 8.94	33.49±11.68	50.33±20.34	0.002
(random)(ng/ml)				
ACTH	5.00(5.00,9.32)	66.40(40.25,128.00)	220.50(83.45,328.	< 0.001

(pg/ml)			00)	
Urinary-free	299.00(147.75,503.10)	233.80(130.53,721.70	1212.50(785.00,2	0.001
cortisol)	012.50)	
(mg/24 h)				
FSH(IU/L)	42.04(1.38,68.35)	23.33(2.14,45.13)	1.230(0.78,2.44)	0.012
LH(IU/L)	16.93(1.82,18.79)	9.03(0.18,19.56)	0.150(0.07,0.25)	0.021
E2(pg/ml)	11.00(10.00,16.50)	12.690(10.00,28.50)	16.00(13.10,28.46	0.267
)	
T(ng/dl)	24.15(20.64,39.13)	47.70(33.17,73.56)	85.26(55.85,114.4	0.008
			4)	

Statistically significant results(P<0.05) were highlighted in bold.Comparison between groups was performed using one-way ANOVA or Kruskal-Wallis test if the distribution of the respective variable was not log-normal in any of the groups.ACTH: adrenocorticotrophic hormone; FSH: Follicle-stimulating hormone; LH: Luteinizing hormone; E2: estradiol; T: testosterone.

Table3. Characteristics of steroid profile in 45 women with CS

	Adrenal Cushing's	Cushing's disease	P-value
	syndrome	(n=21)	
	(n=24)		
Age	42.75±11.80	39.00±9.84	0.257
(years)			
Body mass index	27.47±4.35	26.81 ± 4.84	0.633
(kg/m2)			
Progesterone	116.00(115.00,217.50)	120.00(100.00,299.50)	0.936
(pg/ml)			
17-hydroxyprogesterone	287.00(240.50,638.75)	532.00(209.00,815.00)	0.481
(pg/ml)			
Testosterone	107.50(96.00,162.75)	238.00(177.00,317.50)	< 0.001
(pg/ml)			
Androstenedione	602.00(107.50,812.75)	1349.00(960.00,2419.50)	< 0.001
(pg/ml)			
DHEA	648.00(556.50,841.00)	4054.00(2589.00,5588.50)	< 0.001
(pg/ml)			
DHEA-S (*10^6)	0.14(0.08, 0.25)	1.87(1.50,2.66)	< 0.001
(pg/ml)			
Cortisol (*10^5)	1.78 ± 0.78	1.90 ± 0.83	0.538
(pg/ml)			
Corticosterone	3142.00(2128.25,6479.00)	3125.00(1320.00,5111.50)	0.328
(pg/ml)			
11-Deoxycortisol	811.50(664.25,1636.00)	609.00(397.00,801.00)	0.011
(pg/ml)			
11-Deoxycorticosterone	106.00(96.00,288.15)	96.000(80.00,96.00)	0.006
(pg/ml)			
Cortisone	20386.13±6388.96	21192.76±8661.66	0.716

(pg/ml)

Statistically significant results(P<0.05) were highlighted in bold. Comparison between groups was performed using one-way ANOVA or Kruskal-Wallis test if the distribution of the respective variable was not log-normal in any of the groups. DHEA, dehydroepiandrosterone; DHEAS, DHEA sulfate.

Table 4. Accuracy of steroid biomarkers for differentiating CD form adrenal CS

	AUC (95% CI)	Sensitivity (%)	Specificity (%)	Youden index
Total	0.816	81.0%	83.3%	0.643
Testosterone(TT)	(0.682, 0.951)			
> 172.5 pg/ml				
Androstenedione (A2)	0.829	100.0%	83.3%	0.875
> 917.5 pg/ml	(0.706, 0.952)			
DHEA	0.972	100.0%	87.5%	0.875
> 1170.5 pg/ml	(0.934, 1.000)			
DHEA-S	0.958	100.0%	83.3%	0.833
> 0.27*10^6 pg/ml	(0.899, 1.000)			

The AUCs with 95% confidence intervals of the four different androgen were included. The sensitivity and specificity for each marker were derived from the optimal cutoff value. AUC: area under the curve; CI: confidence interval; DHEA dehydroepiandrosterone; DHEAS DHEA sulfate.




Figure 1. Scatter plots of reproductive hormones. Estradiol, testosterone, LH and FSH values are displayed in (A)-(C), respectively. All comparison between the three subgroups are shown by brackets, asterisks or text. E2, estradiol; FSH, Follicle-stimulating hormone; LH, Luteinizing hormone; AI-CS, ACTH-independent Cushing's syndrome; CD, Cushing's disease; EAS, ectopic ACTH syndrome. ***, P<0.001; ns, not significant.




Figure 2. Linear regressions between serum cortisol and reproductive hormones in premenopausal and postmenopausal women. Premenopausal women with Cushing's syndrome were included in (A)-(C). Postmenopausal women with CS were included in (D)-(F) to avoid effects of the menstrual cycle. Pearson correlations(r) were calculated squares. FSH, Follicle-stimulating hormone; LH, Luteinizing hormone.




Figure 3. ROC-analysis to different between adrenal CS and CD with plasma androgens. ROC-analysis to differentiate between patients with AI-CS and CD with the most discriminative steroids. TT, total testosterone; A2, androstenedione; DHEA, dehydrospiandrostenedione; DHEAS, dehydrospiandrostenedione sulfate.




Figure4. Scatter plots of Thyroid hormone.Serum FT3,FT4 ,TSH and FT3/FT4 values are displayed in(A)-(D).All comparison between the three subgroups are shown by brackets,asterisks or text. TSH: thyroid-stimulating hormone; AI-CS, ACTH-independent Cushing's syndrome; CD, Cushing's disease; EAS, ectopic ACTH syndrome. ***, P<0.001; **, P<0.01; *, P<0.05; ns, not significant.